CC-95775 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CC-95775’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CC-95775 (FT-1101) is under development for the treatment of relapsed or refractory acute myeloid leukemia, relapsed or refractory B-cell non hodgkin lymphomas including diffuse large B-cell lymphoma, solid tumors including basal cell carcinoma, primary mediastinal lymphoma, unspecified B-cell lymphoma and high-risk myelodysplastic syndrome. It is administered through oral route as capsule. The drug candidate is a benzopiperazine derivative which acts by targeting bromo and extra terminal (BET) family members BRD2, BRD3, BRD4, BRDT.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of CC-95775’s drug-specific PTSR and LoA scores, buy the report here.